Literature DB >> 25434727

Regulatory network of differentially expressed genes in metastatic osteosarcoma.

Peng Yao1, Zhi-Bin Wang1, Yuan-Yuan Ding1, Jia-Ming Ma1, Tao Hong1, Shi-Nong Pan2, Jin Zhang3.   

Abstract

The present study aimed to investigate the possible molecular mechanisms underlying the pathogenesis of metastatic osteosarcoma (OS), by examining the microarray expression profiles of normal samples, and metastatic and non‑metastatic OS samples. The GSE9508 gene expression profile was downloaded from the Gene Expression Omnibus database, which included 11 human metastatic OS samples, seven non‑metastatic OS samples and five normal samples. Pretreatment of the data was performed using the BioConductor package in R language, and the differentially expressed genes (DEGs) were identified by a t‑test. Furthermore, function and pathway enrichment analyses of the DEGs were conducted using a molecule annotation system. A differential co‑expression network was also constructed, and the submodules were screened using MCODE in Cytoscape. A total of 965 genes were identified as DEGs in metastatic OS. The DEGs were shown to participate in the regulation of DNA‑dependent transcription, the composition of the nucleus, cytoplasm and membrane, and protein and nucleotide binding. Furthermore, the screened DEGs were significantly associated with the ribosome, axon guidance and the cytokine‑cytokine receptor interaction pathway. Certain hub genes were identified in the constructed differential co‑expression network, including matrix metalloproteinase 1 (MMP1), smoothened (SMO), ewing sarcoma breakpoint region 1 (EWSR1) and fasciculation and elongation protein ζ‑1 (FEZ1). Brain selective kinase 2 (BRSK2) and aldo‑keto reductase family 1 member B10 (AKRIB10) were present in the screened submodules. The results of the present study suggest that genes, including MMP1, SMO, EWSR1, FEZ1, BRSK2 and AKRIB10, may be potential targets for the diagnosis and treatment of metastatic OS.

Entities:  

Mesh:

Year:  2014        PMID: 25434727     DOI: 10.3892/mmr.2014.3009

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  4 in total

Review 1.  Hedgehog signaling inhibitors as anti-cancer agents in osteosarcoma.

Authors:  Ram Mohan Ram Kumar; Bruno Fuchs
Journal:  Cancers (Basel)       Date:  2015-05-13       Impact factor: 6.639

2.  Tectorigenin inhibits osteosarcoma cell migration through downregulation of matrix metalloproteinases in vitro.

Authors:  Yu Guo; Ya-Hong Chen; Zhi-Hua Cheng; Huo-Niu Ou-Yang; Cong Luo; Zhi-Lin Guo
Journal:  Anticancer Drugs       Date:  2016-07       Impact factor: 2.248

3.  Identification of Upstream Kinases by Fluorescence Complementation Mass Spectrometry.

Authors:  Lingfei Zeng; Wen-Horng Wang; Justine Arrington; Gengbao Shao; Robert L Geahlen; Chang-Deng Hu; W Andy Tao
Journal:  ACS Cent Sci       Date:  2017-09-13       Impact factor: 14.553

4.  Delineation of hypoxia-induced proteome shifts in osteosarcoma cells with different metastatic propensities.

Authors:  Zifeng Song; Martin C Pearce; Yuan Jiang; Liping Yang; Cheri Goodall; Cristobal L Miranda; Milan Milovancev; Shay Bracha; Siva K Kolluri; Claudia S Maier
Journal:  Sci Rep       Date:  2020-01-20       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.